The Weizmann Institute of Science (WIS) is at the forefront of research and treatment innovation. The collaboration with Steba Biotech led to the formation of Steba Laboratories, a research centre that enables the production and rapid targeting of new compounds prior to an in-depth pre-clinical assessment.
Memorial Sloan Kettering Center (New York, USA)
The collaboration with Memorial Sloan-Kettering, a global leader in cancer research and treatment, initially involved conducting clinical trials and has evolved into an active research and development programme focusing on the treatment of prostate cancers as well as other localized tumours.
The active research and development programme widely benefits from the collaboration between researchers at the Weizmann Institute and the main MSKCC research teams specialised in various cancers.
University of Oxford
Steba Biotech is currently partnering with the University of Oxford and the NIHR (National Institute for Health Research) in the UK to conduct the PART study. PART stands for Partial prostate Ablation versus Radical Treatment and is a landmark randomized trial, comparing TOOKAD to radical prostatectomy or radiotherapy among intermediate risk prostate cancer patients with unilateral disease.